nd a patented vapor deposition process that creates a metallic strut configuration resembling cancellous bone with a nano-textured surface. Trabecular Metal
Technology is exclusive to Zimmer.
"This clinical study is the first to directly compare bone-remodeling effects of a low stiffness porous metal construct to more rigid traditional titanium hip implants at a mid-term follow-up, and highlights potential advantages attributed to Trabecular Metal technology," said Cheryl R. Blanchard, PhD, Zimmer's Senior Vice President and Chief Scientific Officer. "It demonstrates that Zimmer's unique Trabecular Metal products may significantly reduce bone loss after surgery and may improve long term biologic fixation."
For more information about Zimmer, visit www.zimmer.com
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2008 sales were approximately $4.1 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.
Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "prPage: 1 2 3 4 5 Related medicine technology :1
. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series2
. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis3
. Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients4
. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome5
. Reliv Internationals GlucAffect(TM) Proven Effective in Clinical Study6
. Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program7
. GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas8
. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series9
. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial10
. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial11
. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis